13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0000200406
Total reported value
$798.7M
$798.7M
22 檔
524.8%
In Q1 2024, Johnson & Johnson's U.S. equity holdings reached a combined market value of $798.7M, distributed across 22 disclosed stock positions.
During Q1 2024, Johnson & Johnson's portfolio maintained high stability with no major positional turnover, reflecting a continuous long-term holding approach.
In terms of portfolio concentration, the top 5 core holdings (including KVUE, FUSION PHARMACEUTICALS INC, CVRX) accounted for 524.8% of total reported equity market value during Q1 2024.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | KVUE | Kenvue Inc | Stock-Consumer Staples | 88.66% | — | — | |
| 2 | ✓ | Fusion Pharmaceuticals Inc | Stock-Other | 1.77% | — | — | |
| 3 | CVRX | Cvrx Inc | Stock-Other | 1.69% | -3.25% | +17.39% | |
| 4 | PTGX | Protagonist Therapeutics Inc | Stock-Other | 1.61% | -1.98% | — | |
| 5 | SWAVUSD | Shockwave Medical Inc | Stock-Other | 1.23% | — | — | |
| 6 | LEGN | Legend Biotech Corp-adr | Stock-Other | 1.04% | +0.69% | — | |
| 7 | MGTX | MeiraGTx Holdings plc | Stock-Other | 0.91% | +2.41% | — | |
| 8 | NBTX | Nanobiotix SA - Adr | Stock-Other | 0.83% | -0.06% | — | |
| 9 | NMRA | Neumora Therapeutics Inc | Stock-Other | 0.58% | -0.16% | — | |
| 10 | FATE | Fate Therapeutics Inc | Stock-Other | 0.56% | +0.52% | — | |
| 11 | PRCT | Procept Biorobotics CORP | Stock-Other | 0.40% | -0.36% | — | |
| 12 | XNCR | Xencor Inc | Stock-Other | 0.38% | +0.13% | — | |
| 13 | ARWR | Arrowhead Pharmaceuticals In | Stock-Healthcare | 0.16% | — | — | |
| 14 | VOR | Vor Biopharma Inc. | Stock-Other | 0.06% | — | — | |
| 15 | NNOX | Nano-X Imaging Ltd. | Stock-Other | 0.04% | -0.03% | EXIT | |
| 16 | ALDX | Aldeyra Therapeutics Inc | Stock-Other | 0.02% | — | — | |
| 17 | ✓ | Biomx Inc | Stock-Other | 0.02% | — | -9.85% | |
| 18 | TORCEUR | Adicet Bio Inc | Stock-Other | 0.02% | — | -47.07% | |
| 19 | LAB | Standard Biotools Inc | Stock-Other | 0.02% | -0.01% | — | |
| 20 | CLSDUSD | Clearside Biomedical Inc | Stock-Other | 0.01% | — | — | |
| 21 | ✓ | Stock-Other | — | — | — | ||
| 22 | SENS1GBP | Senseonics Holdings Inc | Stock-Other | — | — | — |
According to official SEC Form 13F filings, Johnson & Johnson reported a total U.S. public equity portfolio value of $798.7M across 22 disclosed positions in Q1 2024.
During Q1 2024, Johnson & Johnson's top holdings by market value included KVUE (88.7%)、FUSION PHARMACEUTICALS INC (1.8%)、CVRX (1.7%). The largest single position, KVUE, represented 88.7% of total portfolio value.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In Q1 2024, Johnson & Johnson made 0 total portfolio adjustments, initiating 0 new buys, adding to 0 positions, trimming 0 holdings, and fully liquidating 0 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.